Current status of FK 506 in liver transplantation.
نویسندگان
چکیده
In 1987 Ochiai and coworkers presented a report on the immunosuppressive qualities of a new immunosuppressive agent, FK 506, isolated from the fermented broth of a soil fungus, Streptomyces tsukubaensis.1 Extensive in vitro studies demonstrated the effectiveness in suppressing mixed lymphocyte cultures, presumably by inhibiting 1L-2 synthesis following ailoactivation.2 The receptor for FK 506 has been identified and has been characterized as a peptidyl-prolyl cis-trans isomerasc.3
منابع مشابه
Infections in adult liver transplant patients under FK 506 immunosuppression.
THE preliminary results of infectious complications in orthotopic liver transplantation IOLT) using FK 506 as a primary immunosuppressive agent were encouraging. I This early experience. however. was limited to only 20 patients who were followed for a short period of time. We have now extended our observations to 110 consecutive adult liver transplant recipients of first livers enrolled in the ...
متن کاملOne thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.
FK 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989. 1 and I year later at the Thirteenth International Congress of Transplantation Society. San Francisco. CA 1990. extensive reports were given from our center describing the p...
متن کاملSingle-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.
OBJECTIVE The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined. SUMMARY BACKGROUND DATA After 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejecti...
متن کاملRandomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.
THE USE of cyclosporine (CyA) has greatly impacted the success of liver transplantation. FK 506 is a newly described immunosuppressive agent, with mechanisms of action similar to those of Cy A, but more potent on a weight-ta-weight basis. Pilot studies of FK 506 in primary liver transplantation have shown encouraging results. 1 A randomized trial using FK 506 with low-dose steroids (LDS) was co...
متن کاملIntravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.
FK 506 is a new macrolide with potent immunosuppressive activity. Use of this drug is associated with reduced incidence of rejection following liver. kidney. and heart transplantation. 1-4 Recently, FK 506 has been shown to be effective in small bowel transplantation. S It is known that FK 506 absorption is not influenced by the presence or absence of bile.6--8 The aims of this study are to: (\...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Transplantation proceedings
دوره 23 3 شماره
صفحات -
تاریخ انتشار 1991